未知股票 BPTH 深 滬
已收盤
--
0.000
NaN.00%
華盛通- 最 高--
- 今 開--
- 成交量 --
- 最 低 --
- 昨 收 --
- 總市值 0
- 52周最高 --
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 總股本 830.79万
- 歷史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 歷史最低 --
- 每 手 1
- 風險率 1.62%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Bio-Path Holdings Q2 EPS $(0.55) Misses $(0.40) Estimate
Bio-Path Holdings (OTC:BPTH) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.40) by 37.5 percent. This is a 52.59 percent increase over losses of $(1.16) per share from
08-15 05:42
Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum
Bio-Path Holdings, Inc. announced that CEO Peter Nielsen will present a corporate overview at the Life Sciences Virtual Investor Forum on June 12. The company, leveraging its DNAbilize® technology, is developing a portfolio of targeted nucleic acid drugs for cancer and obesity. Its lead candidates include prexigebersen (BP1001) in Phase 2 for blood cancers and BP1001-A in Phase 1/1b for solid tumors and obesity. BP1002 targets Bcl-2 protein for b...
06-09 11:00
Bio-Path Holdings Highlights Pipeline Progress And Market Strategy For DNAbilize Platform
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity
06-03 19:13
Bio-Path Holdings Provides Clinical and Operational Update
Bio-Path Holdings is leveraging its DNAbilize® platform to develop new drug candidates for oncologic and cardiometabolic diseases. Key highlights include progress in clinical trials for Prexigebersen (for AML), BP1001-A (for solid tumors), and BP1002 (for AML). The company also explored Prexigebersen's potential for treating obesity in Type 2 diabetes patients. Bio-Path plans to file an IND application for BP1003 and expects to achieve several mi...
06-03 11:00
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Healthcare Triangle (NASDAQ:HCTI) shares increased by 81.7% to $0.87 d...
02-18 20:05
快讯 | Bio-Path Holdings提供了关于BP1002用于治疗难治性/复发性急性髓系白血病的1期/10亿临床试验的更新
Bio-Path Holdings Provides Update From Phase 1/1B Clinical Trial of BP1002 for ...
02-13 05:01
Bio-Path Holdings Advances Clinical Pipeline for 2025
Bio-Path Holdings ( ($BPTH) ) has issued an announcement. Bio-Path Holdings ann...
01-11 05:53
Bio-path Provides A Clinical Development And Operational Update For 2025
Clinical Program OverviewBio-Path's clinical development program consists of one Phase 2 clinical trial, two Phase 1 or 1/1b clinical trials, and two preclinical programs. Bio-Path has developed a molecular biomarker
01-10 20:21
暴涨406%并熔断！这一医药公司火了
Bio-Path Holdings股价盘中暴涨超406%，报3.39美元，并触发熔断机制。其后，其股价逐渐回落，至收盘时报1.49美元，仍上涨122.72%。
2024-12-20 11:24
Bio-Path Holdings: Promising Preclinical Results for BP1001-A
Bio-Path Holdings ( ($BPTH) ) has provided an announcement. Bio-Path Holdings h...
2024-12-20 05:58
